Literature DB >> 15950355

Cisplatin-mediated DNA double-strand breaks in replicating but not in quiescent cells of the yeast Saccharomyces cerevisiae.

Marlis Frankenberg-Schwager1, Dorothea Kirchermeier, Goetz Greif, Karin Baer, Manuela Becker, Dieter Frankenberg.   

Abstract

DNA double-strand breaks (DSBs) are formed during the processing of DNA interstrand crosslinks in replicating yeast and Chinese hamster cells exposed to DNA crosslinkers such as psoralen plus UVA or nitrogen mustard. They were also detected in human cells after treatment with photoactivated psoralen or mitomycin C. In contrast, no DSBs were observed after exposure of Chinese hamster cells to cisplatin, another crosslinking agent widely used for the therapy of various cancers, challenging a common role for DSBs in the processing of DNA interstrand crosslinks. Here we report for the first time that cisplatin-mediated DSBs are induced in replicating but not quiescent cells of the yeast Saccharomyces cerevisiae. When the main pathway of repair of DSBs is inhibited, these breaks accumulate in replicating cells. Thus it appears that DNA interstrand crosslinks induced by different crosslinking agents, including cisplatin, are processed yielding DSBs as an intermediate lesion. In stationary cells, however, removal of DNA interstrand crosslinks after cisplatin treatment occurs without the formation of DSBs. These findings point to an altered mode of processing of cisplatin-DNA adducts in replicating versus quiescent cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950355     DOI: 10.1016/j.tox.2005.04.015

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  17 in total

Review 1.  Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

Authors:  Xiangyi Lu; Li Xiao; Luan Wang; Douglas M Ruden
Journal:  Biochem Pharmacol       Date:  2011-11-22       Impact factor: 5.858

2.  EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.

Authors:  Heike N Pfäffle; Meng Wang; Liliana Gheorghiu; Natalie Ferraiolo; Patricia Greninger; Kerstin Borgmann; Jeffrey Settleman; Cyril H Benes; Lecia V Sequist; Lee Zou; Henning Willers
Journal:  Cancer Res       Date:  2013-08-21       Impact factor: 12.701

Review 3.  DNA interstrand crosslink repair and cancer.

Authors:  Andrew J Deans; Stephen C West
Journal:  Nat Rev Cancer       Date:  2011-06-24       Impact factor: 60.716

4.  Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers.

Authors:  Ting Luo; Jianqing Yu; Jenny Nguyen; Chun-Rong Wang; Robert G Bristow; David A Jaffray; Xiao Zhen Zhou; Kun Ping Lu; Qing-Bin Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-08       Impact factor: 11.205

5.  SUMOylation is developmentally regulated and required for cell pairing during conjugation in Tetrahymena thermophila.

Authors:  Amjad M Nasir; Qianyi Yang; Douglas L Chalker; James D Forney
Journal:  Eukaryot Cell       Date:  2014-12-19

Review 6.  Molecular mechanisms of resistance and toxicity associated with platinating agents.

Authors:  Cara A Rabik; M Eileen Dolan
Journal:  Cancer Treat Rev       Date:  2006-11-03       Impact factor: 12.111

7.  DNA replication factor C1 mediates genomic stability and transcriptional gene silencing in Arabidopsis.

Authors:  Qian Liu; Junguo Wang; Daisuke Miki; Ran Xia; Wenxiang Yu; Junna He; Zhimin Zheng; Jian-Kang Zhu; Zhizhong Gong
Journal:  Plant Cell       Date:  2010-07-16       Impact factor: 11.277

Review 8.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  RhoB promotes γH2AX dephosphorylation and DNA double-strand break repair.

Authors:  Kenza Mamouni; Agnese Cristini; Josée Guirouilh-Barbat; Sylvie Monferran; Anthony Lemarié; Jean-Charles Faye; Bernard S Lopez; Gilles Favre; Olivier Sordet
Journal:  Mol Cell Biol       Date:  2014-06-09       Impact factor: 4.272

10.  TRAIL treatment provokes mutations in surviving cells.

Authors:  M M Lovric; C J Hawkins
Journal:  Oncogene       Date:  2010-07-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.